107 related articles for article (PubMed ID: 38496564)
1. Combinatorial
Hebert JD; Tang YJ; Andrejka L; Lopez SS; Petrov DA; Boross G; Winslow MM
bioRxiv; 2024 Mar; ():. PubMed ID: 38496564
[TBL] [Abstract][Full Text] [Related]
2. Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response
Foggetti G; Li C; Cai H; Hellyer JA; Lin WY; Ayeni D; Hastings K; Choi J; Wurtz A; Andrejka L; Maghini DG; Rashleigh N; Levy S; Homer R; Gettinger SN; Diehn M; Wakelee HA; Petrov DA; Winslow MM; Politi K
Cancer Discov; 2021 Jul; 11(7):1736-1753. PubMed ID: 33707235
[TBL] [Abstract][Full Text] [Related]
3. Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
Yousefi M; Andrejka L; Winslow MM; Petrov DA; Boross G
bioRxiv; 2023 Feb; ():. PubMed ID: 36778226
[TBL] [Abstract][Full Text] [Related]
4. Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
Yousefi M; Andrejka L; Szamecz M; Winslow MM; Petrov DA; Boross G
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2303224120. PubMed ID: 37695905
[TBL] [Abstract][Full Text] [Related]
5. A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer.
Cai H; Chew SK; Li C; Tsai MK; Andrejka L; Murray CW; Hughes NW; Shuldiner EG; Ashkin EL; Tang R; Hung KL; Chen LC; Lee SYC; Yousefi M; Lin WY; Kunder CA; Cong L; McFarland CD; Petrov DA; Swanton C; Winslow MM
Cancer Discov; 2021 Jul; 11(7):1754-1773. PubMed ID: 33608386
[TBL] [Abstract][Full Text] [Related]
6. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
7. Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis.
Schuster K; Venkateswaran N; Rabellino A; Girard L; Peña-Llopis S; Scaglioni PP
Mol Cancer Res; 2014 Jun; 12(6):912-23. PubMed ID: 24618618
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
9. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.
McFadden DG; Politi K; Bhutkar A; Chen FK; Song X; Pirun M; Santiago PM; Kim-Kiselak C; Platt JT; Lee E; Hodges E; Rosebrock AP; Bronson RT; Socci ND; Hannon GJ; Jacks T; Varmus H
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6409-E6417. PubMed ID: 27702896
[TBL] [Abstract][Full Text] [Related]
10. Diminishing-returns epistasis among random beneficial mutations in a multicellular fungus.
Schoustra S; Hwang S; Krug J; de Visser JA
Proc Biol Sci; 2016 Aug; 283(1837):. PubMed ID: 27559062
[TBL] [Abstract][Full Text] [Related]
11. LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer.
Murray CW; Brady JJ; Han M; Cai H; Tsai MK; Pierce SE; Cheng R; Demeter J; Feldser DM; Jackson PK; Shackelford DB; Winslow MM
Nat Commun; 2022 Feb; 13(1):1090. PubMed ID: 35228570
[TBL] [Abstract][Full Text] [Related]
12. Widespread epistasis among beneficial genetic variants revealed by high-throughput genome editing.
Ang RML; Chen SA; Kern AF; Xie Y; Fraser HB
Cell Genom; 2023 Apr; 3(4):100260. PubMed ID: 37082144
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.
Zhang H; Nabel CS; Li D; O'Connor RÍ; Crosby CR; Chang SM; Hao Y; Stanley R; Sahu S; Levin DS; Chen T; Tang S; Huang HY; Meynardie M; Stephens J; Sherman F; Chafitz A; Costelloe N; Rodrigues DA; Fogarty H; Kiernan MG; Cronin F; Papadopoulos E; Ploszaj M; Weerasekara V; Deng J; Kiely P; Bardeesy N; Vander Heiden MG; Chonghaile TN; Dowling CM; Wong KK
J Thorac Oncol; 2023 Jul; 18(7):882-895. PubMed ID: 36958689
[TBL] [Abstract][Full Text] [Related]
14. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
[TBL] [Abstract][Full Text] [Related]
15. Diminishing returns from beneficial mutations and pervasive epistasis shape the fitness landscape for rifampicin resistance in Pseudomonas aeruginosa.
MacLean RC; Perron GG; Gardner A
Genetics; 2010 Dec; 186(4):1345-54. PubMed ID: 20876562
[TBL] [Abstract][Full Text] [Related]
16. Negative epistasis between beneficial mutations in an evolving bacterial population.
Khan AI; Dinh DM; Schneider D; Lenski RE; Cooper TF
Science; 2011 Jun; 332(6034):1193-6. PubMed ID: 21636772
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer.
Zhao X; Li J; Liu Z; Powers S
Cancer Res; 2021 Dec; 81(24):6090-6105. PubMed ID: 34561273
[TBL] [Abstract][Full Text] [Related]
18. ETS1 regulates Twist1 transcription in a Kras
Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
[TBL] [Abstract][Full Text] [Related]
19. Additive Phenotypes Underlie Epistasis of Fitness Effects.
Sackman AM; Rokyta DR
Genetics; 2018 Jan; 208(1):339-348. PubMed ID: 29113978
[TBL] [Abstract][Full Text] [Related]
20. The consistency of beneficial fitness effects of mutations across diverse genetic backgrounds.
Pearson VM; Miller CR; Rokyta DR
PLoS One; 2012; 7(8):e43864. PubMed ID: 22937113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
